Amid a deteriorating macroeconomic backdrop, orthopedic industry stocks have shown resiliency relative to the broader public markets. This enables management teams to breathe a sigh of relief, driven in part by expectations for a long-awaited pickup in procedure volumes, as they and investors have watched valuations tumble over recent years due to COVID-19 headwinds, supply-chain backlogs, and other industry forces.
Published in MedTech Strategist
Authors: Oded Ben-Joseph, PhD, Thomas F. Busby, and
Derrick Holmes, CFA
Abstract:
Amid a deteriorating macroeconomic backdrop, orthopedic industry stocks have shown resiliency relative to the broader public markets. This enables management teams to breathe a sigh of relief, driven in part by expectations for a long-awaited pickup in procedure volumes, as they and investors have watched valuations tumble over recent years due to COVID-19 headwinds, supply-chain backlogs, and other industry forces.
BOSTON– February 26, 2025 – Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, congratulates RealizedCare on the success of their company, and acquisition by XRHealth. Outcome Capital served as the exclusive strategic and financial advisor to RealizedCare. Through their digitally-powered care management triage platform and therapeutic solutions, RealizedCare […]
Read MoreOutcome Capital Life Science Market Pulse January 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?